Introduction: Despite major advances with biologics and small molecules, many patients with IBD continue to have refractory disease or lose treatment response. This Perspective explores engineered cellular therapies designed to restore immune tolerance rather than simply suppress inflammation.
Introduction:
Despite major advances with biologics and small molecules, many patients with IBD continue to have refractory disease or lose treatment response. This Perspective explores engineered cellular therapies designed to restore immune tolerance rather than simply suppress inflammation.
Why was this article needed?
Current therapies effectively control inflammation but rarely correct the underlying immune dysfunction. Cellular immunotherapy offers the potential for durable remission through immune reprogramming.
Clinical Impact:
Engineered cellular therapies could transform the management of refractory IBD, particularly in patients with multiple biologic failures. However, these therapies remain investigational and require validation in well-designed prospective clinical trials.
Bottom Line:
Stem cells, Tregs, Tr1 cells, and CAR T-cell platforms represent the next generation of IBD therapy, with the potential to restore immune tolerance and achieve durable disease modification beyond conventional immunosuppression.
Introduction: The global incidence of inflammatory bowel disease (IBD) continues to rise, particularly in newly industrialized countries. This comprehensive systematic review evaluated how race, ethnicity, geography, and migration influence the clinical phenotype and outcomes of...
Introduction: Acute severe ulcerative colitis (ASUC) remains one of the most life-threatening emergencies in inflammatory bowel disease. Despite advances in IBD therapy, first-line management has changed little over the past two decades, and colectomy continues...
Introduction: Ulcerative colitis (UC) is a chronic inflammatory bowel disease with a rising global burden. Although current therapies are effective, many patients fail treatment or experience adverse effects. Fecal microbiota transplantation (FMT) has emerged as...
Introduction: Randomized clinical trials (RCTs) are the cornerstone for approving biologic therapies in inflammatory bowel disease (IBD). However, strict eligibility criteria may exclude many patients encountered in routine clinical practice, raising concerns about the real-world...
Introduction: Mirikizumab, a selective IL-23p19 inhibitor, has demonstrated efficacy in phase III clinical trials for moderate-to-severe ulcerative colitis (UC). This multicenter Italian real-world study evaluated its effectiveness and safety in routine clinical practice, including patients...
Introduction: Mirikizumab, a selective IL-23p19 inhibitor, has demonstrated efficacy in phase III clinical trials for moderate-to-severe ulcerative colitis (UC). This multicenter Italian real-world study evaluated its effectiveness and safety in routine clinical practice, including patients...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.